Regulatory News
Thursday, August 11, 2016
Gilead to get attorney fees in hepatitis C patent fight with Merck
Aug 11 (Reuters) - Gilead Sciences Inc is entitled
to receive the attorney fees it incurred related to hepatitis C
patent litigation with drugmaker Merck & Co Inc, a U.S.
district judge has ruled.
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment